A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

The study, published in British scientific journal Nature, suggests that the disease may begin in basal stem cells — long-lived cells that help repair and replace damaged tissue in the lungs — ...

A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer ...

If you or a loved one has lung cancer, you may be interested in learning more about medicines used to treat it. One option is an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

On the heels of two FDA approvals in lung cancer treatments, what innovations are next? As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung ...

How Does Libtayo Work for Non-Small-Cell Lung Cancer (NSCLC)? Libtayo is a specific kind of medicine called immunotherapy. Immunotherapies work by helping your body’s own immune system work to fight ...

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common complication of small cell lung cancer (SCLC). It can cause many symptoms related to low sodium or other electrolyte ...

Ask a clinical question and tap into Healio AI's knowledge base. Lung cancer in general, and non-small cell lung cancer (NSCLC) in particular, is often asymptomatic in the early stages of the disease.